Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer

Tivantinib is a selective, oral, non-ATP-competitive, small molecule inhibitor of the c-Met receptor, tyrosine kinase, which is implicated at different levels of tumor cell migration, invasion, proliferation, and metastasis. Tivantinib has shown antitumor activity in various human tumor cell lines a...

Descripción completa

Detalles Bibliográficos
Autores principales: Broggini, Massimo, Garassino, Marina Chiara, Damia, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559079/
https://www.ncbi.nlm.nih.gov/pubmed/23378782
http://dx.doi.org/10.2147/CMAR.S29995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559079/
https://www.ncbi.nlm.nih.gov/pubmed/23378782
http://dx.doi.org/10.2147/CMAR.S29995

Ejemplares similares